Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on February 17, 2026. The report discloses an amendment to the employment agreement of Robert J. Bitterman, the Company's President and Chief Executive Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes
The primary material change disclosed is the execution of the "Second Amendment" to Mr. Bitterman's employment agreement, effective February 17, 2026. Key modifications include:
- Severance Provision: In the event of termination without "cause" or resignation for "good reason," severance is now set at twelve (12) months of base salary.
- Target Bonus: The annual target bonus opportunity has been increased from 40% to 50% of base salary.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, financial guidance, or specific risk factors. The document notes that the summary of the amendment is qualified in its entirety by reference to the full agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Review Exhibit 10.1 to verify the full definitions of "cause" and "good reason" within the amended agreement.
- Confirm the current base salary of Robert J. Bitterman to calculate the specific monetary value of the increased severance and bonus.
- Check for any related proxy statements or prior filings to understand the historical context of the compensation changes.